Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer

Launched by TONGJI HOSPITAL · Apr 6, 2021

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Experimental group:
• • 1. 18 years old ≤ age ≤ 75 years old, no gender limitation;
• • 2. NSCLC who have received radiotherapy for brain lesions + PD-1/PD-L1 immunotherapy;
• • 3. Histologically confirmed as NSCLC;
• • 4. Imaging confirmed brain metastasis (CT or MRI);
• • 5. The presence of imaging-evaluable lesions can be evaluated in accordance with RECIST 1.1
• Control group:
• • 1 18 years old ≤ age ≤ 75 years old, no gender limitation; 2 NSCLC who has received radiotherapy for brain lesions; 3 Histologically confirmed as non-small cell lung cancer; 4 Imaging confirmed brain metastasis (CT or MRI); 5 The presence of imaging-evaluable lesions can be evaluated in accordance with RECIST 1.1
• • -
• Exclusion Criteria:
• • 1 The age is less than 18 years old, regardless of gender; 2 Histologically confirmed as NSCLC 3 Imaging confirmed the absence of brain metastases 4 NSCLC with brain metastasis only received chemotherapy or targeted therapy, and did not receive radiotherapy or immunotherapy
• • -